These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 22023062)

  • 1. Creation of a de novo, pharmaceutical company with a urological bent.
    Wyllie MG
    BJU Int; 2011 Nov; 108(9):E310-1. PubMed ID: 22023062
    [No Abstract]   [Full Text] [Related]  

  • 2. Alternative business models for drug discovery.
    Bunin BA; Ekins S
    Drug Discov Today; 2011 Aug; 16(15-16):643-5. PubMed ID: 21745585
    [No Abstract]   [Full Text] [Related]  

  • 3. Increase in R&D openness to tackle disease in the developing world.
    Parks L
    Future Med Chem; 2012 Dec; 4(18):2237. PubMed ID: 23234547
    [No Abstract]   [Full Text] [Related]  

  • 4. The value of drug repositioning in the current pharmaceutical market.
    Tobinick EL
    Drug News Perspect; 2009 Mar; 22(2):119-25. PubMed ID: 19330170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug discovery: new models for industry-academic partnerships.
    Tralau-Stewart CJ; Wyatt CA; Kleyn DE; Ayad A
    Drug Discov Today; 2009 Jan; 14(1-2):95-101. PubMed ID: 18992364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An unbalanced portfolio.
    Federsel HJ
    Drug News Perspect; 2009 Jun; 22(5):287-92. PubMed ID: 19609466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How to revive breakthrough innovation in the pharmaceutical industry.
    Munos BH; Chin WW
    Sci Transl Med; 2011 Jun; 3(89):89cm16. PubMed ID: 21715677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How should we support pharmaceutical innovation?
    Grootendorst P
    Expert Rev Pharmacoecon Outcomes Res; 2009 Aug; 9(4):313-20. PubMed ID: 19670991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Dismantling of "Big Pharma" gives new impetus to the pharmaceutical sector. Dynamic life science clusters can increase Swedish competitiveness].
    Hedner T; Gatenbeck L
    Lakartidningen; 2012 Jun 27-Jul 17; 109(26-28):1280-1. PubMed ID: 22852257
    [No Abstract]   [Full Text] [Related]  

  • 10. Does process excellence handcuff drug development?
    Koenig J
    Drug Discov Today; 2011 May; 16(9-10):377-81. PubMed ID: 21349347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Portfolio management in early stage drug discovery - a traveler's guide through uncharted territory.
    Betz UA
    Drug Discov Today; 2011 Jul; 16(13-14):609-18. PubMed ID: 21600301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug development risk and the cost of capital.
    Baras AI; Baras AS; Schulman KA
    Nat Rev Drug Discov; 2012 Apr; 11(5):347-8. PubMed ID: 22498751
    [No Abstract]   [Full Text] [Related]  

  • 13. Open innovation: share or die..
    Talaga P
    Drug Discov Today; 2009 Nov; 14(21-22):1003-5. PubMed ID: 19778629
    [No Abstract]   [Full Text] [Related]  

  • 14. R&D transformation and value-based innovation.
    Epstein RS
    J Comp Eff Res; 2012 Jan; 1(1 Suppl):1-2. PubMed ID: 24237315
    [No Abstract]   [Full Text] [Related]  

  • 15. An audience with...Francis Collins. Interviewed by Asher Mullard.
    Collins F
    Nat Rev Drug Discov; 2011 Jan; 10(1):14. PubMed ID: 21151031
    [No Abstract]   [Full Text] [Related]  

  • 16. Stimulating antibiotic development.
    Tillotson G
    Lancet Infect Dis; 2010 Jan; 10(1):2-3. PubMed ID: 20129141
    [No Abstract]   [Full Text] [Related]  

  • 17. An open source pharma roadmap.
    Balasegaram M; Kolb P; McKew J; Menon J; Olliaro P; Sablinski T; Thomas Z; Todd MH; Torreele E; Wilbanks J
    PLoS Med; 2017 Apr; 14(4):e1002276. PubMed ID: 28419094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug and vaccine development for infectious diseases: the value of priority review vouchers.
    Matheny J; Smith B; Courtney B; Mair M
    Clin Pharmacol Ther; 2009 Jun; 85(6):571-2. PubMed ID: 19451907
    [No Abstract]   [Full Text] [Related]  

  • 19. Multifaceted roles of ultra-rare and rare disease patients/parents in drug discovery.
    Wood J; Sames L; Moore A; Ekins S
    Drug Discov Today; 2013 Nov; 18(21-22):1043-51. PubMed ID: 23968993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New models for pharmaceutical innovation in low-income countries.
    Ardal C; Iversen JH; Myhr K
    Tidsskr Nor Laegeforen; 2011 Oct; 131(20):2016-8. PubMed ID: 22016131
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.